Speedy generic approval may not benefit consumers as much as expected, mathematical model shows

Faster approval times for generic drugs will get them into consumers’ hands quicker, but may not make the price any better, a pricing and marketing researcher has found. A mathematical model shows that fewer firms enter the marketplace because the chances of getting there first and commanding the best profits are dramatically smaller when drug approval times are shorter.